Anemia Clinical Trial
Official title:
Evaluation of Home-Based Management of Fever in Urban Ugandan Children
The purpose of this study is to see if providing effective antimalarial treatment at home for parents/guardians to treat their children for malaria will lead to an improved health outcome compared to conventional healthcare.
Population: Representative sample of Ugandan children aged 1 to 5 years from 400 households
(approximately 540 children).
Clinical Site: The study will be conducted in the Mulago III parish community of Kampala,
Uganda.
Study Duration: 13 months
Study Intervention: *Pilot period: After enrollment, households will participate in a one
month pilot period to test the household pictorial diaries. At the end of the pilot period,
households will be randomized to participation in the home-based management of fever (HBMF)
arm or standard care arm for the remainder of the study (12 months). *HBMF arm: Households
randomized to the HBMF group will be provided with pre-packaged coartemether to keep at
home. Primary caregivers will be instructed to treat children participating in the study
empirically with coartemether at home when the child develops fever. Study personnel will
distribute drugs and educate the caregivers about administration of drugs, recognition of
danger signs of fever/malaria, and when to seek additional care. *Standard care: Households
randomized to the standard care arm will be asked to continue their current behaviour and to
manage fever in their children as they would normally.
Measurements: Household diaries and monthly visits. Primary caregivers will be asked to keep
a diary regarding the health of study participants for the duration of the study (13
months). Information on illnesses, treatments given, visits to health care facilities, and
health care expenditures will be collected. Study personnel will visit the households
monthly to collect completed diaries. At each visit, questionnaires will be administered to
gather additional data on the health of the participants and treatment seeking behaviour.
Clinical and laboratory evaluations: Temperature, height, weight, mid-upper arm
circumference, spleen size, haemoglobin, and thick blood smear will be assessed at
enrollment, and at the beginning and end of the intervention period.
Study Objectives: 1. To measure the impact of home-based management of fever with
coartemether on malaria-related morbidity compared to the current standard of care in the
community.
2. To measure the impact of home-based management of fever with coartemether on economic
measures compared to the current standard of care in the community.
Primary outcome: Treatment incidence density (treatments per time at risk) for each
treatment arm
Secondary clinical outcomes: 1) mean days of fever; 2) incidence of febrile episodes; 3)
mean haemoglobin at study end; 4) change in mean haemoglobin; 5) prevalence of splenomegaly;
6) prevalence of parasitaemia; 7) incidence of visits to health care facilities, and
hospitalizations; 8) mortality rate; 9) anthropometric measurements; 10) proportion of
"appropriate" treatments; 11) proportion of delayed treatments; 12) treatment incidence
density of treatments given at >50% and at full dose
Economic outcomes: 1) household cost/febrile episode; 2) household costs for treatment of
febrile episode/month; 3) provider cost/child for delivery of HBMF; 4) estimated provider
facility cost/patient for uncomplicated fever, and for severe disease; 5) total net
cost/child/year; 6) net cost/additional child appropriately treated; 7) net cost/day of
fever averted
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
| Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
| Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
| Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
| Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
| Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
| Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
| Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
| Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
| Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
| Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
| Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
| Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A | |
| Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |